MedTrace Logo

Sitosterolemia Metabolism

NCT01584206 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 8

Last updated 2020-01-30

No results posted yet for this study

Summary

Ezetimibe has become the treatment choice for patients with sitosterolemia. Ezetimibe is an inhibitor of cholesterol absorption from the gastrointestinal tract. The purpose of this study is to determine if ezetimibe improves whole body plant sterol and cholesterol homeostasis.

Conditions

  • Sitosterolemia

Interventions

DRUG

Ezetimibe

10mg ezetimibe/day, at least 4 months

Sponsors & Collaborators

  • University of Manitoba

    lead OTHER

Principal Investigators

  • Semone B Myrie, PhD · University of Manitoba

  • Peter J Jones, PhD · University of Manitoba

Study Design

Allocation
NA
Purpose
BASIC_SCIENCE
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
16 Years
Max Age
99 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2012-04-30
Primary Completion
2013-08-31
Completion
2016-12-31

Countries

  • Canada

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01584206 on ClinicalTrials.gov